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Abstract
Clinical practice guidelines have been elaborated to summarize
evidence related to the management of knee osteoarthritis and
to facilitate uptake of evidence-based knowledge by clinicians.
The objectives of the present review were summarizing the
recommendations of existing guidelines on knee osteoarthritis,
and assessing the quality of the guidelines using a standardized
and validated instrument – the Appraisal of Guidelines Research
and Evaluation (AGREE) tool. Internet medical literature
databases from 2001 to 2006 were searched for guidelines,
with six guidelines being identified. Thirteen clinician
researchers participated in the review. Each reviewer was
trained in the AGREE instrument. The guidelines were
distributed to four groups of three or four reviewers, each group
reviewing one guideline with the exception of one group that
reviewed two guidelines. One independent evaluator reviewed
all guidelines. All guidelines effectively addressed only a minority
of AGREE domains. Clarity/presentation was effectively
addressed in three out of six guidelines, scope/purpose and
rigour of development in two guidelines, editorial independence
in one guideline, and stakeholder involvement and applicability
in none. The clinical management recommendation tended to be
similar among guidelines, although interventions addressed
varied. Acetaminophen was recommended for initial pain
treatment, combined with exercise and education. Nonsteroidal
anti-inflammatory drugs were recommended if acetaminophen
failed to control pain, but cautiously because of gastrointestinal
risks. Surgery was recommended in the presence of persistent
pain and disability. Education and activity management
interventions were superficially addressed in most guidelines.
Guideline creators should use the AGREE criteria when
developing guidelines. Innovative and effective methods of
knowledge translation to health professionals are needed.
Introduction
Osteoarthritis of the knee affects an important part of the pop-
ulation, causing disability in many individuals and engendering
significant costs [1]. Its prevalence is also increasing, due in
part to the aging of the population [2] and to higher obesity
rates [3]. Clinical practice guidelines in the management of
AAOS = American Academy of Orthopaedic Surgeons; ACR = American College of Rheumatology; AGREE = Appraisal of Guidelines Research and 
Evaluation; CCC = Canadian Consensus Conference; EULAR = European League Against Rheumatism; ICSI = Institute for Clinical Systems 
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osteoarthritis of the knee have been elaborated to summarize
evidence related to the management of this health problem
and to facilitate uptake of evidence-based knowledge by clini-
cians. There has, however, been increased scrutiny of the
quality of guidelines in recent years. This emphasis is in part
related to the relatively recent work of the Appraisal of Guide-
lines Research and Evaluation (AGREE) collaboration, an
'international collaboration of researchers and policy makers
working together to improve the quality and effectiveness of
clinical practice guidelines by establishing a shared framework
for their development, reporting and assessment' [4]. A review
of the quality of knee osteoarthritis guidelines using the
AGREE instrument was published in 2002, concluding that
the quality of the guidelines varied and could generally be
improved [5]. Several guidelines have been published or
updated since then, following the advancements in knowledge
regarding the management of this condition, particularly as it
relates to nonsteroidal anti-inflammatory drugs (NSAIDs) and
their cardiovascular safety.
The present review had the following objectives: to summarize
the recommendations of existing guidelines on knee osteoar-
thritis; and to assess the quality of the guidelines using the
AGREE criteria.
Methods
The following databases were searched in order to find rele-
vant guidelines: Medline, Embase and National Guideline
Clearinghouse (guidelines.gov). The search strategy used was
osteoarthritis and guideline(s) in the title and/or abstract and/
or MESH heading. For selection, the guidelines had to meet
the following criteria: published or updated between 2001 and
August 2006, major focus on knee osteoarthritis, addressing
the treatment of the condition, published in English or French,
and available electronically.
Six guidelines were identified using this search strategy [6-
11]. One guideline was a partial update [7] of a previously
published guideline [12], and both of these were combined for
the evaluation. Four of the guidelines were complete updates
of previously published guidelines [6,8-10], while one guide-
line was entirely new [11]. The quality of prior versions of four
of the guidelines [6-9] had been assessed in a previous review
[5].
These guidelines were distributed to four groups of three or
four evaluators. Each group reviewed one guideline, with the
exception of one group that reviewed two guidelines. One
independent evaluator reviewed all guidelines. In total, 13 cli-
nician researchers (five rheumatologists, three physiothera-
pists, one physiatrist, one occupational health physician, one
psychologist, one family physician, one physician specialized
in medical information) participated in the review. In addition to
the guidelines, each evaluator was asked to read the AGREE
instrument training manual [4] and received a 2-hour training
session. This AGREE tool was used to assess the quality of
the guidelines and has been shown generally reliable [13,14].
The AGREE instrument is composed of 23 items organized
into six domains: scope/purpose, stakeholder involvement, rig-
our of development, clarity/presentation, applicability, and edi-
torial independence. Guidelines with a clear scope/purpose
specifically describe objectives and patient applicability.
Stakeholder involvement is successfully addressed when all
relevant groups, including patients, are included in the guide-
line development process, with target users defined and
guidelines piloted among them. Guidelines with rigour in their
development use systematic methods to search and select
evidence, with an explicit link between evidence and recom-
mendation formulation. In guidelines effectively addressing
clarity/presentation, specific and unambiguous key recom-
mendations and management options are easily identifiable.
Applicability involves discussing cost and organizational impli-
cations of the guideline, and providing monitoring tools. Edito-
rial independence is effectively addressed when conflicts of
interest and independence from funding bodies are clearly
stated.
A domain score is calculated by adding the scores of the items
in a domain and by standardizing the total out of 100%.
Domain scores greater than 60% are considered effectively
addressed, a cutoff value used in the AGREE instrument for
overall assessment [4]. The guideline is strongly recom-
mended if it rates high (three or four out of four) on the majority
of items and most domain scores are above 60%, is recom-
mended if it rates high (three or four) or low (one or two) on a
similar number of items and most domain scores are between
30% and 60%, and is not recommended if it rates low (one or
two) on the majority of items and most domain scores are
below 30% [4].
Each evaluator independently reviewed the guideline that was
assigned to their group, using the AGREE instrument. Each
group then met on two separate occasions with electronic and
telephone exchanges between the meetings. At the last meet-
ing, disagreements on ratings of the individual items were dis-
cussed until a consensus was reached on all items.
Results
Description of guidelines
Table 1 presents the interventions and the time period covered
by the guidelines. Medication and exercises were covered by
almost all guidelines; injections, surgery, education and equip-
ment by most guidelines; with other interventions (supple-
ments and passive treatments) covered by the minority. One
guideline exclusively focused on exercise, while another
focused only on NSAIDs. Most guidelines graded their recom-
mendations according to the strength of evidence [6,8,10,11],
while one guideline graded only some recommendations [9]Available online http://arthritis-research.com/content/9/6/R126
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and another guideline graded none [7]. The grading of criteria,
however, varied among guidelines (Table 2).
AGREE evaluation of guidelines
In general, there were few disagreements among reviewers on
AGREE scores, and all disagreements were resolved after dis-
cussion. Table 3 presents the item scores using the AGREE
instrument, and Table 4 presents the domain scores and over-
all assessment of the guidelines. Only a minority of domains
were effectively addressed by the guidelines. The Canadian
Consensus Conference (CCC) guideline [8], the European
League Against Rheumatism (EULAR) guideline [6], the Insti-
tute for Clinical Systems Improvement (ICSI) guideline [9] and
the Ottawa Panel guideline [11] effectively addressed two
domains, and the American Academy of Orthopaedic Sur-
geons (AAOS) guideline [10] and the Schnitzer/American
College of Rheumatology (ACR) guideline [7] effectively
addressed none. There was variability among guidelines in the
domains effectively addressed.
The Ottawa Panel guideline and the CCC guideline can be
considered to have the highest quality among the guidelines,
since they effectively addressed two domains and came close
to effectively addressing two others (≥ 50%). The Ottawa
Panel guideline effectively addressed scope/purpose and rig-
our of development, but poorly addressed applicability and
editorial independence. The CCC guideline effectively
addressed clarity/presentation and editorial independence,
but poorly addressed scope/purpose and applicability.
Next in quality would be the EULAR and ICSI guidelines, both
effectively addressing two domains and coming close to
addressing another one. The EULAR guideline effectively
addressed rigour of development and clarity/presentation, but
poorly addressed stakeholder involvement, applicability and
editorial independence. The ICSI guideline effectively
addressed scope/purpose and clarity/presentation, but poorly
addressed stakeholder involvement, rigour of development,
and applicability.
Finally, both the AAOS and the Schnitzer/ACR guidelines only
came close to effectively addressing two domains. The AAOS
guideline poorly addressed stakeholder involvement, rigour of
development, applicability, and editorial independence. The
Schnitzer/ACR guideline poorly addressed stakeholder
involvement, rigour of development, clarity/presentation, and
applicability.
On the basis of these scores, none of the guidelines were
strongly recommended. The Ottawa Panel guideline, the CCC
guideline, the EULAR guideline and the ICSI guideline were
recommended, while the AAOS guideline and the Schnitzer/
ACR guideline were not.
Clarity/presentation was the domain most often effectively
addressed by the guidelines (three out of six guidelines), fol-
lowed by scope/purpose and rigour of development (two out
of six guidelines). Editorial independence was effectively
addressed in only one guideline. The most poorly addressed
Table 1
Characteristics of the selected guidelines
Guideline Intervention
Medication Exercise Surgery Injections Equipment Education Supplements Passive
treatments
Period covered 
with literature 
review
Canadian Consensus 
Conference [8]
X 2000–2004
Ottawa Panel [11] X Not mentioned 
(published in 
2005)
Schnitzer/American 
College of 
Rheumatology [7]
XX X X XX N o t  m e n t i o n e d  
(published in 
2002)
European League 
Against Rheumatism 
[6]
X X X X X X X 1966–2002
Institute for Clinical 
Systems Improvement 
[9]
XX X XX X X N o t  m e n t i o n e d  
(published in 
2004)
American Academy of 
Orthopaedic Surgeons 
[10]
X X X X X X 1990–2000Arthritis Research & Therapy    Vol 9 No 6    Poitras et al.
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domains were stakeholder involvement and applicability, with
no guideline effectively addressing these.
Guideline recommendations
Tables 5, 6, 7, 8, 9, 10, 11, 12 summarize the recommenda-
tions of the guidelines according to the intervention category.
There was variability among guidelines in the specificity of the
interventions studied, with some being more general and other
guidelines more detailed. Only one guideline systematically
provided recommendations according to the type of outcome
pursued [11].
Exercises
Exercise was recommended in all guidelines that studied this
intervention (Table 5), with the specificity of recommendations
ranging from very general [6] to very specific [11]. Generally,
lower limb strengthening, mobility and flexibility exercises were
recommended. Aerobic exercises and general physical activity
were also recommended. For the guideline that provided rec-
ommendations according to outcome [11], exercise appeared
to have a positive impact on pain and disability.
Medication and supplements
Acetaminophen was recommended as initial pain treatment in
all guidelines (Table 6). NSAIDs were also recommended, but
combined with a proton pump inhibitor in the presence of high
gastrointestinal risk factors. Alternatively, coxibs were also rec-
ommended. The cardiovascular safety of both NSAIDs and
coxibs was questioned in one guideline [8]. Some guidelines
recommended other drugs if the preceding medications were
either contraindicated or were nonresponsive [6,7,9]. Sympto-
matic slow-acting drugs were recommended in certain guide-
Table 2
Criteria for recommendation grading
Ottawa Panel [11]
A Evidence from one or more randomized controlled trials of a statistically significant, clinically important benefit (>15%)
B Statistically significant, clinically important benefit (>15%) if the evidence is from observational studies or controlled clinical trials
C+ Clinical importance (>15%) but no statistical significance
C No clinically important difference and no statistical significance
D Evidence from one or more randomized controlled trials of a statistically significant benefit favouring the control group
Canadian Consensus Conference [8] and European League Against Rheumatism [6]
A Meta-analysis of randomized controlled trial or at least one randomized controlled trial
B At least one controlled study without randomization or at least one quasi-experimental study
C Descriptive studies, such as comparative, correlation or case–control studies
D Expert committee reports or opinions and/or clinical experience of respected authorities
American Academy of Orthopaedic Surgeons [10]
A Meta-analysis of multiple, well-designed controlled studies; or high-power randomized, controlled clinical trial; or consistent findings from 
multiple well-designed experimental studies; or low-power randomized, controlled clinical trials; or nonexperimental studies such as 
nonrandomized, controlled single-group, pre–post, cohort, time, or matched case–control series; or nonexperimental studies, such as 
comparative and correlational descriptive and case studies
B Generally consistent findings from well-designed experimental studies; or low-power randomized, controlled clinical trials; or 
nonexperimental studies such as nonrandomized, controlled single-group, pre–post, cohort, time, or matched case–control series; or 
nonexperimental studies, such as comparative and correlational descriptive and case studies
C Inconsistent findings from well-designed experimental studies; or low-power randomized, controlled clinical trials; or nonexperimental 
studies such as nonrandomized, controlled single-group, pre–post, cohort, time, or matched case–control series; or nonexperimental 
studies, such as comparative and correlational descriptive and case studies
D Little or no systematic empirical evidence
Institute for Clinical Systems Improvement [9]
1 Strong design study results that are clinically important and consistent. The results are free of any significant doubts about generalizability, 
bias, and flaws in research design. Studies with negative results have sufficiently large samples to have adequate statistical power
2 Strong design study results that are inconsistent or with minor doubts about generalizability, bias, flaws in research design, or adequacy of 
sample size. Alternatively, evidence consists solely of consistent results from weaker designs
3 Strong design study results that are substantially inconsistent or with serious doubts about generalizability, bias, flaws in research design, or 
adequacy of sample size. Alternatively, evidence consists solely of limited results from weaker designsAvailable online http://arthritis-research.com/content/9/6/R126
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lines: glucosamine and chondroitin were recommended in two
guidelines [6,9], while avocado/soya unsaponifiables and
diacerein were recommended in one guideline [6] (Table 7).
Intraarticular injections
Corticosteroid or hyaluronic acid injections were recom-
mended in four of the guidelines [6,7,9,10] (Table 8), but with
less strength of evidence when compared with exercises or
medication. The injections were mostly recommended as sec-
ond-line treatments, with relatively short-term benefits for
corticosteroids.
Surgery
Three guidelines provided recommendations regarding sur-
gery [6,7,10], with one providing detailed recommendations
according to the type of intervention and the patients' condi-
Table 3
Appraisal of Guidelines Research and Evaluation of the guidelines
Appraisal of Guidelines Research and Evaluation criterion EULAR
[6]
Ottawa
Panel [11]
ICSI
[9]
CCC
[8]
AAOS
[10]
Schnitzer/
ACR [7]
Scope/purpose
1. Overall objective(s) specifically described 2 3 2 3 3 3
2. Clinical question(s) specifically described 3 2 4 2 2 3
3. Patients to whom the guideline is meant to apply specifically described 3 4 4 2 3 2
Stakeholder involvement
4. Development group included individuals from all relevant professional groups 2 4 2 4 1 1
5. Patients' views and preferences sought 1 2 1 4 1 2
6. Target users clearly defined 1 4 4 1 4 1
7. Guideline piloted among end users 1 1 1 1 1 1
Rigour of development
8. Systematic methods used to search for evidence 3 3 1 3 2 1
9. Criteria for selecting evidence clearly described 4 4 1 2 1 2
10. Methods used for formulating the recommendations clearly described 3 2 1 1 3 1
11. Health benefits, side effects and risks considered in formulating the 
recommendations
43 2 4 2 4
12. Explicit link between recommendations and supporting evidence 4 4 3 4 2 3
13. Guideline externally reviewed by experts prior to publication 1 3 1 1 2 1
14. Procedure for updating the guideline provided 1 1 3 3 2 1
Clarity/presentation
15. Specific and unambiguous recommendations 3 2 3 2 2 1
16. Different options for diagnosis and/or treatment of the condition clearly 
presented
34 3 4 2 3
17. Key recommendations easily identifiable 4 3 4 4 4 1
18. Guideline supported with tools for application 2 2 4 2 2 1
Applicability
19. Potential organizational barriers in applying the recommendations discussed 1 2 2 1 1 1
20. Potential cost implications of applying the recommendations considered 1 1 1 4 1 2
21. Guideline presents key review criteria for monitoring and audit purposes 1 1 3 1 1 1
Editorial independence
22. Guideline editorially independent from the funding body 3 3 1 4 1 1
23. Conflicts of interest of guideline development members recorded 1 1 4 4 1 4
AAOS, American Academy of Orthopaedic Surgeons; ACR, American College of Rheumatology; CCC, Canadian Consensus Conference; 
EULAR, European League Against Rheumatism; ICSI, Institute for Clinical Systems Improvement. 1, Strongly disagree; 2, disagree; 3, agree; 4, 
strongly agree.Arthritis Research & Therapy    Vol 9 No 6    Poitras et al.
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tion [10] (Table 9). Surgery was generally recommended in
chronic pain patients with moderate to severe disability for
whom conservative treatment had not been effective or was
insufficient.
Passive treatments
Five adjunct treatments, consisting of heat/ice, compression/
elevation, transcutaneous electrical nerve stimulation (TENS),
massage and acupuncture, were recommended in one guide-
line [9] (Table 10). None of the other guidelines provide rec-
ommendations towards other passive treatments.
Equipment
Three categories of equipment were recommended in four of
the guidelines [6,7,9,10]: assistive devices for ambulation and
activities of daily living, knee orthotics, and appropriate foot-
Table 4
Domain scores and overall assessment of the guidelines
Appraisal of Guidelines Research and 
Evaluation domain
EULAR [6] Ottawa Panel [11] ICSI [9] CCC [8] AAOS [10] Schnitzer/
ACR [7]
Scope/purpose (%) 56 67 78 44 56 56
Stakeholder involvement (%) 8 58 33 50 25 8
Rigour of development (%) 62 62 24 52 33 29
Clarity/presentation (%) 67 58 83 67 50 17
Applicability (%) 0 11 33 33 0 11
Editorial independence (%) 33 33 50 100 0 50
Overall quality assessment of the 
guideline
Recommended Recommended Recommended Recommended Not
recommended
Not
recommended
AAOS, American Academy of Orthopaedic Surgeons; ACR, American College of Rheumatology; CCC, Canadian Consensus Conference; 
EULAR, European League Against Rheumatism; ICSI, Institute for Clinical Systems Improvement.
Table 5
Guideline recommendations for exercises
Ottawa Panel [11] AAOS [10] EULAR [6] ICSI [9] Schnitzer/ACR [7]
Exercises Recommended (A)
Lower limb 
strengthening 
exercises
Recommended (A, 
C+ or C depending 
on type and outcome)
Recommended (A) Recommended (1) Recommended
Walking Recommended (A, 
C+ or C depending 
on outcome)
Recommended (1)
Whole-body 
exercises or physical 
activity
Recommended (A or 
C depending on 
outcome)
Recommended (1)
Jogging in water Recommended (A or 
C depending on 
outcome)
Combined lower limb 
strengthening, 
flexibility and mobility 
exercises
Recommended (A or 
C depending on 
outcome)
Aerobic exercises Recommended (A) Recommended (1) Recommended
Lower limb range of 
motion or mobility or 
flexibility exercises
Recommended (A) Recommended (1) Recommended
Manual therapy with 
exercises
Recommended (A or 
C depending on 
outcome)
AAOS, American Academy of Orthopaedic Surgeons; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; 
ICSI, Institute for Clinical Systems Improvement.Available online http://arthritis-research.com/content/9/6/R126
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Table 6
Guideline recommendations for medication
AAOS [10] EULAR [6] ICSI [9] Schnitzer/ACR [7] CCC [8]
Nonselective 
NSAID
Recommended (A) Recommended (A) Recommended if 
acetaminophen not 
effective
Recommended Recommended (A)
Recommended with 
PPI if 
gastrointestinal risk 
factors
Recommended with PPI or 
misoprol if gastrointestinal risk 
factors
Recommended (A) 
with PPI if 
gastrointestinal risk 
factors
Use with caution for patients 
with high risk factors for 
congestive heart failure or renal 
problems
Use with caution with 
elderly patients (C) or 
patients with renal 
problems (D)
Not recommended for patients 
on anticoagulation therapy or 
preoperative period
Topical NSAID Recommended (A) Recommended (A)
Acetaminophen Recommended (A) Recommended (A) 
as initial pain 
treatment
Recommended as 
initial pain 
treatment
Recommended as initial pain 
treatment
Recommended (A) as 
initial pain treatment
Coxibs Recommended (B) if 
renal or 
gastrointestinal risk 
factors
Recommended (A) if 
gastrointestinal risk 
factors
Recommended if 
gastrointestinal risk 
factors
Recommended for patients not 
responding to acetaminophen 
or nonpharmacologic 
modalities
Recommended (A) if 
gastrointestinal risk 
factors, depending on 
cardiovascular risks
Recommended for patients 
with severe pain or signs of 
inflammation
Use with caution with 
elderly patients (C) or 
patients with renal 
problems (D)
Recommended for patients 
with high gastrointestinal risks.
Use with caution for patients 
with high risk factors for 
congestive heart failure or renal 
problems
Tramadol Recommended for patients 
with contraindication to 
NSAIDs/coxibs or who have 
not responded to oral therapy
Opioids Recommended (B) if 
NSAIDs are 
contraindicated
Recommended if 
NSAIDs 
contraindicated 
and if 
nonpharmacologic 
treatments not 
effective
Recommended for patients 
who have not responded to 
tramadol or have side effects
Capsaicin Recommended (A) Recommended as an adjunct 
treatment to oral therapy, for 
patients with contraindication 
to NSAIDs/coxibs or for 
patients who have not 
responded to oral therapy
Nonacetylated 
salicylates
Recommended
Methylsalicylate Recommended as an adjunct 
treatment to oral therapy, for 
patients with contraindication 
to NSAIDs/coxibs or for 
patients who have not 
responded to oral therapy
AAOS, American Academy of Orthopaedic Surgeons; ACR, American College of Rheumatology; CCC, Canadian Consensus Conference; 
EULAR, European League Against Rheumatism; ICSI, Institute for Clinical Systems Improvement; NSAID, nonsteroidal anti-inflammatory drug; 
PPI, proton pump inhibitor.Arthritis Research & Therapy    Vol 9 No 6    Poitras et al.
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wear (Table 11). Referring the patient to a health professional
trained in the use of these equipments was generally
recommended.
Education
Education and weight loss was recommended in four guide-
lines [6,7,9,10] (Table 12), although the term 'education' was
clearly defined in only one guideline [9]. Activity management,
including activities of daily living, leisure, sports and work, was
briefly addressed in three guidelines [7,9,10].
Discussion
The present review highlights the relatively large number of
types of interventions available to clinicians and patients when
managing knee osteoarthritis. Types of interventions included
in the guidelines varied, reflecting choices made by develop-
ment teams. It appears that interventions with the strongest
evidence tended to be addressed in most guidelines (such as
exercise and medication), while other interventions with less
evidence tended to be addressed in a minority of guidelines.
There was also variability in the level of details of interventions,
with some guidelines dividing a category of intervention into
various forms, and others succinctly describing only the cate-
gory. The interests, mandate and resources of the develop-
ment team probably guided the type and extent of
interventions addressed.
When comparing guidelines, there generally seemed to be
agreement in recommendations on the interventions
addressed. Acetaminophen was generally recommended for
initial pain treatment. Introducing more potent medication,
such as NSAIDs, was also generally suggested if acetami-
nophen failed to control pain. The gastrointestinal risks
associated with NSAID intake was stressed in the guidelines,
however, especially with patients with high gastrointestinal risk
factors. Only the most recent guideline [8] discussed the car-
diovascular safety of NSAIDs following the 2005 advice by the
American Food and Drug Agency [15]. This seems to highlight
the slowness of guidelines to react to important emerging
data. This observation also shows that guidelines can rapidly
become outdated, especially in fields of rapid knowledge
advancements. For the guidelines included in the present
review that were updates [6-10], there was a delay of 1–7
years between versions, with a mean of 3.8 years. These
results are probably biased by the fact that most of the
included guidelines were published in peer-reviewed journals,
involving delays for publication. The two guidelines that were
not published in peer-reviewed journals [9,10], however, had
the shortest (1 year) and longest (7 years) delays between ver-
sions. Innovative knowledge translation methods, allowing the
rapid integration of new evidence by clinicians, should be
developed and implemented.
Exercise and education were also generally recommended
throughout all disease stages. The type of exercise
recommended varied among guidelines, but it appears the
important notion is to keep active, whatever the type of exer-
cise. Although education was frequently suggested, its ele-
ments were not well described in the guidelines, apart from
one [9]. Perhaps this is related to the relative lack of evidence
Table 7
Guideline recommendations for symptomatic slow-acting drugs
EULAR [6] ICSI [9]
Glucosamine Recommended (A) Recommended
Chondroitin Recommended (A) Recommended
Avocado/soya unsaponifiables Recommended (B)
Diacerein Recommended (B)
EULAR, European League Against Rheumatism; ICSI, Institute for Clinical Systems Improvement.
Table 8
Guideline recommendations for intraarticular injections
AAOS [10] EULAR [6] ICSI [9] Schnitzer/ACR [7]
Corticosteroid Recommended (D)
if inflammation
Recommended (B) Recommended Recommended as adjunct treatment to oral therapy, for 
patients with contraindication to NSAIDs/coxibs or for patients 
who have not responded to oral therapy
Hyaluronic acid Recommended (B) Recommended (2) Recommended as adjunct treatment to oral therapy, for 
patients with contraindication to NSAIDs/coxibs or for patients 
who have not responded to oral therapy
AAOS, American Academy of Orthopaedic Surgeons; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; 
ICSI, Institute for Clinical Systems Improvement; NSAID, nonsteroidal anti-inflammatory drug.Available online http://arthritis-research.com/content/9/6/R126
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Table 9
Guideline recommendations for surgery
AAOS [10] Schnitzer/ACR [7] EULAR [6]
Surgery Recommended for patients with 12 
weeks or more of pain not responding 
to conservative treatment
Recommended for patients with 
severe osteoarthritis limiting their 
activities of daily living and not 
responding to nonpharmacologic and 
pharmacologic treatments
Recommended (C) for patients with 
radiographic evidence of 
osteoarthritis, refractory pain and 
disability
Total knee replacement Recommended (A) for patients with 
bi/tri compartmental arthritis if no 
response from conservative treatment
Recommended (C)
Recommended (A) for patients with 
medial compartment arthritis not 
candidate for osteotomy or 
unicompartmental knee replacement
Recommended (A) for patients with 
lateral compartment arthritis not 
candidate for osteotomy
Recommended (B) for older patients 
if magnetic resonance imaging 
confirms avascular necrosis
Recommended (B) for older or less 
active patients with isolated 
patellofemoral arthritis
Recommended (D) if no response 
from conservative treatment and 
previous infection
Not recommended (D) if active 
infection
Unicompartmental knee 
replacement
Recommended (B) for less active 
patients with medial compartment 
arthritis
Recommended (C)
Recommended (C) for patients with 
lateral compartment arthritis not 
candidate for osteotomy
Osteotomy Recommended (A) for young, active 
patients with medial compartment 
arthritis and varus alignment if no 
response from conservative treatment
Recommended (C)
Recommended (B) for young, active 
patients with lateral compartment 
arthritis
Arthroscopy Not recommended (A) if no 
mechanical symptoms
Recommended (C)
Recommended (B) if degenerative 
arthritis and mechanical symptoms
Recommended (B) if gross 
malalignment/instability, cartilage 
remaining and localized symptoms
Knee fusion Recommended (D) if no response 
from conservative treatment and 
previous infection, or for young 
patients with a history of chronic 
infection
Patellectomy Recommended (D) for young, active 
patients with isolated patellofemoral 
arthritis
AAOS, American Academy of Orthopaedic Surgeons; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism.Arthritis Research & Therapy    Vol 9 No 6    Poitras et al.
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regarding the effectiveness of specific messages given to
patients. Activity management was also not detailed in the
guidelines, although knee osteoarthritis often has an important
impact on the patient's functional capacities [1]. Referral to an
occupational therapist was sometimes suggested to help in
this management. Future guidelines should specify education
and activity management interventions, in order to help in their
application.
Surgery was generally recommended as a last resort in the
presence of persistent pain and disability. Other interventions
were suggested in some of the guidelines, such as intraarticu-
lar injections, supplements, equipment and passive therapies,
but their role and place in the management of knee osteoarthri-
tis was unclear. This is probably related to the weaker evi-
dence regarding the effectiveness of these interventions. The
role of these interventions should be specified in future
guidelines.
AGREE evaluation of guidelines
The AGREE evaluation demonstrated that the guidelines
effectively addressed only a minority of domains. Although
scope/purpose, rigour of development and clarity/presenta-
tion were the most often effectively addressed domains, the
Table 10
Guideline recommendations for passive treatments
Institute for Clinical Systems Improvement [9]
Cold/heat Recommended
Compression/elevation Recommended
Massage Recommended if heat/cold and medications are contraindicated or not effective
Transcutaneous electrical nerve stimulation (TENS) Recommended if heat/cold and medications are contraindicated or not effective
Acupuncture Recommended if heat/cold and medications are contraindicated or not effective
Table 11
Guideline recommendations for equipment
AAOS [10] EULAR [6] ICSI [9] Schnitzer/ACR [7]
Assistive devices for ambulation or 
activities of daily living
Recommended (B) Recommended Recommended Recommended
Orthotic devices/braces/taping Recommended (B) Recommended (B) Recommended if heat/cold and 
medications are contraindicated or not 
effective
Recommended
Appropriate footwear or insoles Recommended (B) Recommended (B) Recommended if heat/cold and 
medications are contraindicated or not 
effective
Recommended
AAOS, American Academy of Orthopaedic Surgeons; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; 
ICSI, Institute for Clinical Systems Improvement.
Table 12
Guideline recommendations for education
AAOS [10] EULAR [6] ICSI [9] Schnitzer/ACR [7]
Education Recommended (D) Recommended (A) Recommended Recommended
Weight loss if obese Recommended (B) Recommended (B) Recommended Recommended
Activity management or joint protection Recommended (B) Recommended Recommended
Social support Recommended (B) Recommended
Stress management/relaxation Recommended
AAOS, American Academy of Orthopaedic Surgeons; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; 
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majority of guidelines failed to appropriately address these
domains. Guideline developers should focus on the AGREE
criteria constituting these domains in the elaboration of future
guidelines.
Three domains were particularly not well addressed by the
guidelines: stakeholder involvement, applicability, and editorial
independence. In an AGREE evaluation of low-back pain
guidelines, very similar results were obtained [16]. It therefore
appears that guidelines in general have difficulty addressing
these dimensions, and several hypotheses can be elaborated
to explain this. Regarding editorial independence, this was
often simply not mentioned in the guidelines. It is not possible
to know whether this was an error of omission or whether there
were conflicts of interest. Guideline developers should explic-
itly mention editorial links.
As for stakeholder involvement, it appears that a change in the
attitude of guideline developers could be needed. Guideline
developing teams tended not to include all relevant stakehold-
ers and patients. It is, however, suggested that involving
stakeholders in guideline elaboration tends to improve appli-
cability of the recommendations and to facilitate appropriation
among end users [17]. Although there is evidence describing
ways to facilitate this collaboration [18,19], guideline develop-
ers are perhaps unaware of this literature or are uncomfortable
in sharing power and responsibilities, especially with patients.
Guideline developers should be made aware of the literature
on stakeholder involvement and its advantages, and methods
facilitating this collaboration should be developed and used.
As for guideline applicability, barriers in guideline use should
be taken into account during guideline development, in order
to facilitate use and uptake [20,21]. Expecting guideline devel-
opers to address comprehensively this domain while develop-
ing the guideline, however, is perhaps unrealistic. A more
incremental approach to guideline development has been sug-
gested [22], in which a guideline is elaborated with stakehold-
ers taking into account potential barriers raised during the
process. This is followed by piloting the guideline with end
users and collecting organizational and financial barriers with
monitoring instruments. Taking into account these results, a
final version of the guideline is elaborated before general diffu-
sion and implementation. The cost-effectiveness of such a
process, however, remains to be demonstrated.
It appears that the AGREE criteria are more and more taken
into account when elaborating guidelines. The two most
recent guidelines [8,11] had the highest quality and were the
only ones mentioning the use of the AGREE instrument in the
elaboration. Even these guidelines, however, failed to effec-
tively address the majority of domains. Producing a high-qual-
ity guideline effectively addressing all AGREE domains
appears to remain a challenge.
Conclusion
Therapeutic interventions addressed in the guidelines varied,
with no guideline addressing all interventions. When an inter-
vention was addressed in two or more guidelines, the corre-
sponding clinical management recommendation tended to be
similar among guidelines. Acetaminophen was recommended
for initial pain treatment, combined with exercise and educa-
tion. NSAIDs were recommended if acetaminophen failed to
control pain, but cautiously because of gastrointestinal risks.
Surgery was recommended in the presence of persistent pain
and disability. Education and activity management interven-
tions were superficially addressed in most guidelines and
should be detailed in the future. Guidelines effectively
addressed only a minority of AGREE domains. In order to
improve applicability and to increase uptake by end users,
stakeholder opinions and barriers in use need to be taken into
account during guideline development. The apparent slow-
ness of guideline development processes to integrate and dis-
seminate new knowledge means that innovative methods of
knowledge translation to health professionals should be
developed.
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